People with HIV/AIDS (PHAs) who use corticosteroids and/or anti-HIV therapy may be at increased risk for the development of thinner, more porous bones — a condition called osteoporosis. As bones become thinner they can easily break or fracture. The best course of action to prevent and treat osteoporosis in PHAs is not yet clear and researchers are experimenting with different strategies. In a letter published in the August 1, 2001 issue of the journal Clinical Infectious Diseases, researchers in Italy reported that the bone-building treatment Fosamax (alendronate) has helped one PHA recover from osteoporosis. We now report the details of their report.
According to the team, the 51-year-old PHA had been on a HAART regimen consisting of indinavir (Crixivan), 3TC (lamivudine, Epivir) and d4T (Stavudine) for three years. His CD4+ count was 522 cells and his viral load was less than 50 copies. While walking one day, he hurt his back; X-rays of his spine revealed a fracture in one of his back bones. This damage grew worse after a short period of time, and eventually part of his back bone began to collapse, causing severe disability and pain. Doctors prescribed the following regimen, in addition to his existing HAART regimen, to help rebuild his bones:
Before the PHA began this treatment, bone scans found that he had severe osteoporosis in his spine. After six months of treatment, the thickness of his bones increased by about 20% and he said that his pain was "almost completely relieved." Also after six months the PHA developed high levels of lactic acid in his blood — a side effect of anti-HIV therapy. As a result, he had to stop taking all his medications, including nutrients.
The Italian researchers noted that doctors in Australia have recently linked the development of high levels of lactic acid to thinning bones in PHAs. As well, the Italian researchers hope that their favourable report about Fosamax encourages other teams to study the safety and effectiveness of this drug in people using HAART.
For background information on bone health and lactic acidosis see TreatmentUpdate 117.
REFERENCE
Guaraldi G, Ventura P, Albuzza M, et al. Alendronate treatment for osteoporosis in patients infected with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001;33:414-415.
20010710
CATE11901
Copyright © 2001 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
